



Athena Speciality Care



New science, increasing R&D, new technologies and increased specialisation in medicine, has driven the rise of specialty pharmaceuticals. Often, confined to, or coordinated by Hospital based teams, Specialty Medicines in anti-infectives, oncology, neurology, inflammation, orphan and genetic illness, have become a predominant focus for biotech companies, at the nexus of the human genome and Biopharmaceuticals.

Invariably, more precise treatment for fewer patients incurs much greater drug costs. Moreover, the use of such medicines in more complex patient illnesses requires greater medical and scientific understanding of disease processes, biology, pharmacology and toxicity. It also requires a more joined up clinical system and a Holistic approach to the patient.

Biologics, gene therapies etc., hold enormous promise. But the skills base in pharmaceuticals required to support such specialty medicines in the market require ever higher competence in clinical engagement and understanding.

Athena's speciality care team has experience in specific patient cohorts, orphan disease indications and treatments and the introduction of expensive new treatments into hospital formularies and standards of care in oncology, anaesthetics and haematology.

RISE OF
SPECIALTY
PHARMA

KNOWLEDGE
& SKILLS TO
SUPPORT

EXPERT
SPECIALITY
CARE TEAM